Loading
A phase 3 trial of Izalontamab brengitecan, Capecitabine, Gemcitabine in nasopharyngeal carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) is a phase 3 interventional study registered as NCT06118333 by Sichuan Baili Pharmaceutical Co., Ltd., with 386 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2026-11. Interventions recorded: BL-B01D1, capecitabine, gemcitabine, docetaxel. Conditions listed: Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Nasopharyngeal carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Nasopharyngeal carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Docetaxel, Capecitabine.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Docetaxel.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Docetaxel, Gemcitabine.
Shares SystImmune / Sichuan Biokin, Capecitabine, Gemcitabine.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares SystImmune / Sichuan Biokin, Capecitabine, Gemcitabine.